Local Production of Pharmaceuticals and Related Technology Transfer UNCTAD/CD-TFT 1. Background
|
|
- Jemima Cummings
- 5 years ago
- Views:
Transcription
1 Local Production of Pharmaceuticals and Related Technology Transfer Dr. Padmashree Gehl Sampath Division for Technology and Logistics UNCTAD UNCTAD/CD-TFT 1 1 Background Case studies part of the EU funded project titled Improving Access to Medicines through Local Production and Related Technology Transfer of Medical Products Project under the GSPA, Element 4 that urges Member States to promote technology transfer for local production of medical products in developing countries 13 Outputs of the first phase of the project: 8 case studies, 2 global reports on trends of local production and technology transfer apart from some work on vaccines and diagnostics. UNCTAD/CD-TFT 2 2 UN Copyright
2 Selection of firms was based on four models of ToT 1. South-South Transfer of Technology Related to Local Production of Pharmaceuticals (Bangladesh, Ethiopia and Uganda) 2. North-South Transfer of Technology Related to Local Production of Pharmaceuticals (Colombia and Indonesia) 3. State-Supported Creation of Domestic Technological Capacities Related to Production of Pharmaceuticals (Thailand) 4. Creation by Local Private Sector of Domestic Technological Capacities Related to Production of Pharmaceuticals (Argentina and Jordan) UNCTAD/CD-TFT 3 3 Methodology and Purpose A case study approach was used to understand the firm level and country level circumstances that impacted upon actors ability to engage and benefit from technology transfer initiatives for local production. Country level factors were analyzed from the perspective of the individual firm (micro level). Focus was on three main aspects: What factors triggered off the transfer of technology in the pharmaceutical firms in question? How did this lead to building capacity? What system-specific, country specific aspects played a key role in this endeavor? To what extent can the experience of the firm be generalized at the sectoral level? 4 4 UN Copyright
3 1. General Findings: issues of definition 1. What is local production Is it only (geographical, only indigenous firms or including MNC subsidiaries)? Is it production that entails technological learning of some sort, if so how much learning is good? How can different forms of learning (finished formulation and APIs be accommodated)? Is it for simple therapeutic products or for more complex drugs that cater to PH needs? 2. What is access to medicines in the context of LP? UNCTAD/CD-TFT 5 5 UNCTAD/CD-TFT 6 UN Copyright
4 2. Specific Findings Local production is feasible and ongoing in developing and least developed countries Technology transfer has been an important factor in making production feasible and competitive in three important ways: Expanding export markets and product portfolios Meeting quality standards required for exports and safe domestic use Technology transfer for API production helps to increase the competitiveness of local production UNCTAD/CD-TFT Specific Findings Local Production Promotes Access to Medicines in four ways: offers price-based competition in the market, ensuring cheaper prices of drugs and greater affordability. caters to specific health needs of developing by promoting incremental innovations that produce generics of existing drugs. produce new products (in segments that are not catered to by the global pharma) that meet local needs. Promote rural access UNCTAD/CD-TFT 8 8 UN Copyright
5 3. Specific Findings for Africa: Competitiveness, Economics and Finance Much technology transfer is for HIV/AIDS, Malaria. ToT in other pharma areas needs to be introduced (e.g. Type I, II and III diseases, medical devices, vaccines, etc.). More ToT is needed for APIs. Vaccine production should be given priority (capital intensive during start up but low operating cost). Building on existing relationships to form a base for ToT (e.g. Ethiopia, Uganda) Producing already abundant medicines is not the way forward (e.g. paracetamol). Creating specialization building on comparative advantage is necessary by identifying undersupplied markets where demand exists (to benefit from economies of scale). 9 9 UNCTAD/CD-TFT 9 3. Specific Findings: Know-how, technology and innovation The importance of a coordinated government approach to science technology and innovation policy that also promotes investment strategically. Industry needs Government to take a leadership role in promoting a conducive and coherent environment. Level of development of a country will determine the amount of support for the private sector. Importance of partnerships and regional collaboration between national R&D facilities and between private sector and universities. UNCTAD/CD-TFT UN Copyright
6 3. Specific Findings: Good Manufacturing Practices, Regulation, Standards Quality Control Regulatory requirements are needed to ensure the quality, safety, and efficacy of products. There are barriers in meeting these requirements: There is a lack of financing to meet GMP and licensing requirements. There is lack of human resource capacity of regulatory authorities, including skills, personnel, as well as funding. This contributes to longer timeframes for marketing approval of local products. There is limited local capacity to undertake safety and efficacy/bioequivalence studies, clinical trials and other studies required for product registration.. UNCTAD/CD-TFT THANK YOU Padmashree.gehl.sampath@unctad.org UNCTAD/CD-TFT UN Copyright
7 1. General Findings: issues of definition 3. What is innovation and technology transfer for LP? Innovation as any new products, processes and organisational changes that are new to the enterprise, context and country in question, although not necessarily to the world at large. Technology transfer was defined as all components of technology, both codified (in terms of blue prints, hardware, machine parts and plant technologies) and tacit (know-how and skills) that are essential to enhance the capacity of the organizations in the recipient country to produce pharmaceutical products UNCTAD/CD-TFT 13 UN Copyright
Draft Plan of Action Chair's Text Status 3 May 2008
Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background
More informationGlobal strategy and plan of action on public health, innovation and intellectual property
SIXTY-FIRST WORLD HEALTH ASSEMBLY WHA61.21 Agenda item 11.6 24 May 2008 Global strategy and plan of action on public health, innovation and intellectual property The Sixty-first World Health Assembly,
More informationBrazilian industry s activities for international convergence. Walker Lahmann Director of External Trade at ABIFINA Executive Director at Eurofarma
Brazilian industry s activities for international convergence Walker Lahmann Director of External Trade at ABIFINA Executive Director at Eurofarma Mission Congregate companies, institutes and association
More informationVACCINE MANUFACTURING IN DEVELOPING COUNTRIES
VACCINE MANUFACTURING IN DEVELOPING COUNTRIES PERSPECTIVES ON APPROACHES TO TAKE, AND FACTORS TO CONSIDER, TOWARDS SUSTAINABLE MANUFACTURING CAPABILITY Martin Nicholson Pharmaceutical Expert, Dept. of
More informationImplementing Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property in the Eastern Mediterranean Region
Implementing Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property in the Eastern Mediterranean Region 1 Table of Contents LIST OF ACRONYMS AND ABBREVIATIONS -----------------------------------------------------------------------------------
More informationASEAN Regulatory Harmonisation and Approval Process
ASEAN Regulatory Harmonisation and Approval Process Selvaraja Seerangam National Pharmaceutical Control Bureau Ministry of Health Malaysia Open Forum on Key Issues on TB Drug Development- 18-19 August
More informationProblems and Prospects of the Development of Import Substitution in Pharmaceutical Industry of the Russian Federation
Problems and Prospects of the Development of Import Substitution in Pharmaceutical Industry of the Russian Federation Doi:10.5901/mjss.2016.v7n1s1p121 Abstract Larisa Kiseleva Perm branch of the Russian
More informationBrief Note Survey of Indian Pharmaceutical Enterprises for Meeting National and Global Health Needs
Brief Note Survey of Indian Pharmaceutical Enterprises for Meeting National and Global Health Needs Background The pharmaceutical sector is one of the key 25 sectors identified by the Government of India
More informationPriority Theme 1: Science, Technology and Innovation (STI) for the Post-2015 Agenda
UN Commission on Science and Technology for Development 2013-2014 Inter-sessional Panel 2-4 December 2013 Washington D.C., United States of America Priority Theme 1: Science, Technology and Innovation
More informationPromoting innovation and improving access
NATIONAL ASSESSMENT TOOL TO ASSIST MEMBER STATES IN IMPLEMENTING THE GLOBAL STRATEGY AND PLAN OF ACTION ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY INTRODUCTION Promoting innovation and improving
More informationDynamics of National Systems of Innovation in Developing Countries and Transition Economies. Jean-Luc Bernard UNIDO Representative in Iran
Dynamics of National Systems of Innovation in Developing Countries and Transition Economies Jean-Luc Bernard UNIDO Representative in Iran NSI Definition Innovation can be defined as. the network of institutions
More informationTRIPS and Access to Medicines. WR Briefing
TRIPS and Access to Medicines WR Briefing Outline What is TRIPS How does it affect access to medicines What are the TRIPS flexibilities? What are extra-trips provisions? How do the extra-trips provisions
More informationObservations from Pharma
Observations from Pharma Indian Patent Enforcement in the Chemical Arts Gurmeet Kaur Sidhu, Senior Patent Litigation Counsel London, 26/9/11 a Novartis company The Indian Pharmaceutical sector: Overview
More informationStrategic Management of Innovative Development of the Russian Pharmaceutical Complex
MPRA Munich Personal RePEc Archive Strategic Management of Innovative Development of the Russian Pharmaceutical Complex Natalia Klunko 2013 Online at https://mpra.ub.uni-muenchen.de/54381/ MPRA Paper No.
More informationHigh Level Seminar on the Creative Economy and Copyright as Pathways to Sustainable Development. UN-ESCAP/ WIPO, Bangkok December 6, 2017
High Level Seminar on the Creative Economy and Copyright as Pathways to Sustainable Development UN-ESCAP/ WIPO, Bangkok December 6, 2017 Edna dos Santos-Duisenberg creative.edna@gmail.com Policy Advisor
More informationLocal Production for Access to Medical Products: Developing a Framework to Improve Public Health
Local Production for Access to Medical Products: Developing a Framework to Improve Public Health Intellectual Property and Trade R&D, Innovation Technology Transfer Improving Access Financing Monitoring
More informationDraft global strategy on public health, innovation and intellectual property
IGWG: Outcome document at 14.00 hours, Saturday 3 May 2008 Draft global strategy on public health, innovation and intellectual property The context 1. In resolution WHA59.24 the Health Assembly recognized
More informationHTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:
HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually
More information70 th World Health Assembly May 2017 MSF Briefing on Medical Research and Development
70 th World Health Assembly May 2017 MSF Briefing on Medical Research and Development Overview Médecins Sans Frontières (MSF) welcomes the increased attention by WHO and Member States to find ways to ensure
More informationAn Essential Health and Biomedical R&D Treaty
An Essential Health and Biomedical R&D Treaty Submission by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, Third
More informationIP Strategies to Enhance Competitiveness: India s Experience
IP Strategies to Enhance Competitiveness: India s Experience N. N. Prasad Wednesday July 15, 2009 Innovation in Brazil, India and South Africa: A New Drive for Economic Growth and Development Strategy
More informationWritten Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
More informationDecember Eucomed HTA Position Paper UK support from ABHI
December 2008 Eucomed HTA Position Paper UK support from ABHI The Eucomed position paper on Health Technology Assessment presents the views of the Medical Devices Industry of the challenges of performing
More informationColombia on the Frontier of Biomedicine. Zagaya
Colombia on the Frontier of Biomedicine An Intersectorial Meeting for Research, Innovation and Health February 27 & 28, 2012 Hotel Intercontinental, Cali, Colombia Kay Monroe, Executive Director Zagaya
More informationTRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4
TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY 1 12 14 March 2012 Pretoria, South Africa SESSION 4 ACCESS TO MEDICINE: COMMERCIALISATION, DISTRIBUTION, COMPETITION ----------------- Exploitation
More informationThe value of innovative pharmaceuticals and the potential for Vietnam. Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016
The value of innovative pharmaceuticals and the potential for Vietnam Mr. Koen Kruytbosch, Vice-Chairman of Pharma Group Vietnam 6 th October, 2016 PHARMA GROUP Our priority is to ensure that Vietnamese
More informationTechnology transfer and development: implications of four case studies Session 2
Technology transfer and development: implications of four case studies Session 2 Short courses for Permanent Missions in Geneva Monday, 15 December 2014 Michael Lim Policy Review Section Division on Technology
More informationElements of a global strategy and plan of action
INTERGOVERNMENTAL WORKING GROUP A/PHI/IGWG/1/5 ON PUBLIC HEALTH, INNOVATION AND 8 December 2006 INTELLECTUAL PROPERTY Agenda item 2.3 Elements of a global strategy and plan of action Progress to date in
More informationDiscovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.
Discovery: From Concept to the Patient - The Business of Medical Discovery Todd Sherer, Ph.D. Associate Vice President for Research and Director of OTT President Elect, Association of University Technology
More informationHigher Education for Science, Technology and Innovation. Accelerating Africa s Aspirations. Communique. Kigali, Rwanda.
Higher Education for Science, Technology and Innovation Accelerating Africa s Aspirations Communique Kigali, Rwanda March 13, 2014 We, the Governments here represented Ethiopia, Mozambique, Rwanda, Senegal,
More informationSTATE ADVANCED MANUFACTURING POLICIES AND PROGRAMS. As at February 2018
ANNEXURE STATE ADVANCED MANUFACTURING POLICIES AND PROGRAMS As at February 2018 Queensland The Queensland Advanced Manufacturing 10-Year Roadmap and Action Plan was finalised in December 2016 after consultation
More informationWOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview
Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context
More informationSmart Cities. Smart Cities Indicator Survey Highlights
Smart Cities Smart Cities Indicator Survey Highlights 2017 Executive Summary 150 Leaders 12 Countries Smart City Program Offices shaping smart city initiatives Key drivers Economic development Public safety
More informationCronos Capital
Cronos Capital overview Overview Cronos Group, formerly known as PharmaCan Capital Corp., is a vertically integrated cannabis company with great geographical diversification as the foundation for growth
More informationPROPOSAL TEMPLATE. Patent Duration and Collusive Behaviour to Postpone R&D for Innovative Treatments
PROPOSAL TEMPLATE Proposal Name: Patent Duration and Collusive Behaviour to Postpone R&D for Innovative Treatments Submitted by: Pr. Patrick Leoni - Euromed Management (France) E-mail: patrick.leoni@euromed-management.com
More informationA digital health age how to take on the challenges of this advancing field
Page 1 of 7 Custom Search HOME NEWS OPINION TECHNOLOGY ANALYSIS LATEST ISSU 20 September 2017 11:39 A digital health age how to take on the challenges of this advancing field by Norbert Haberland RSS Print
More informationIPR instruments: patents and geographical indications
UNCTAD/CD-TFT 1 IPR instruments: patents and geographical indications ABS and Intellectual Property Rights Addis Abeba, Ethiopia, 5-9 September 2011 Christoph Spennemann, Legal Expert, IP Unit Division
More information9 Vaccine SMEs' Needs
9 Vaccine SMEs' Needs As in most innovative sectors, SMEs play a critical role in bridging basic discoveries from academic research to clinical development 36. This could be seen over the last decade with
More informationVenture Capital Search Highlights
Venture Capital Venture funding continued at the strongest pace witnessed over the past decade in 2016, and recruiting the future leaders of the industry s emerging growth companies has never been more
More informationStanding Committee on the Law of Patents Twenty-Sixth Session
Standing Committee on the Law of Patents Twenty-Sixth Session Marco M. ALEMAN Director, Patent Law Division, WIPO Geneva, July 3 to 6, 2017 SCP/26/5 CONSTRAINTS FACED BY DEVELOPING COUNTRIES AND LEAST
More informationThe case for quality
The case for quality Around the world, up to two billion people lack access to quality essential medicines. Poor-quality medicines undermine the treatment of some of the world s most pressing diseases,
More informationFINLAND. The use of different types of policy instruments; and/or Attention or support given to particular S&T policy areas.
FINLAND 1. General policy framework Countries are requested to provide material that broadly describes policies related to science, technology and innovation. This includes key policy documents, such as
More informationIntellectual Property, Vaccine Production and Technology Transfer
Intellectual Property, Vaccine Production and Technology Transfer Vaccine Industry Perspective P. Fournier, On behalf of IFPMA Bio Group 19-20 April 2004, WHO HQ, Geneva 1 OUTLINE General considerations
More informationB) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:
INTERGOVERNMENTAL WORKING GROUP ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY EGA Submission to Section 1 Draft Global Strategy and Plan of Action The European Generic Medicines Association is
More informationThe Policy Content and Process in an SDG Context: Objectives, Instruments, Capabilities and Stages
The Policy Content and Process in an SDG Context: Objectives, Instruments, Capabilities and Stages Ludovico Alcorta UNU-MERIT alcorta@merit.unu.edu www.merit.unu.edu Agenda Formulating STI policy STI policy/instrument
More informationStanding Committee on the Law of Patents
E SCP/24/4 ORIGINAL: ENGLISH DATE: JUNE 29, 2016 Standing Committee on the Law of Patents Twenty-Fourth Session Geneva, June 27 to 30, 2016 PROPOSAL BY THE AFRICAN GROUP FOR A WIPO WORK PROGRAM ON PATENTS
More informationDigital Health Startups A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationGermany s contribution to the United Nations Secretary-General s High-Level Panel on Access to Medicines
Berlin, 26 February 2016 Germany s contribution to the United Nations Secretary-General s High-Level Panel on Access to Medicines ONLINE SUBMISSION Section 1: Abstract Briefly describe your contribution:
More informationACP/84/047/02 Final Cape Town, 28 July 2002 PAHD Dept. CAPE TOWN DECLARATION ON RESEARCH FOR SUSTAINABLE DEVELOPMENT
ACP/84/047/02 Final Cape Town, 28 July 2002 PAHD Dept. CAPE TOWN DECLARATION ON RESEARCH FOR SUSTAINABLE DEVELOPMENT Cape Town, Republic of South Africa, 28 th July 2002 CAPE TOWN DECLARATION ON RESEARCH
More informationTechnology Transfer and Climate Change: International Flows, Barriers and Frameworks
Brookings Global Economy and Development Climate Change Trade and Investment Washington, DC June 8, 2008 Technology Transfer and Climate Change: International Flows, Barriers and Frameworks 1 Dr. Brian
More informationAfrican Civil Society Meeting
African Civil Society Meeting Intergovernmental Working Group on Intellectual Property, Innovation and Health Topic: Considering Domestic Manufacturing Issues Nairobi Kenya 28-29 August 2007 DR W.O. WANYANGA
More informationTowards a Prosperous Pakistan: A Strategy for Rapid Industrial Growth
Towards a Prosperous Pakistan: A Strategy for Rapid Industrial Growth Pakistan Development Forum Federal Minister Industries, Production & Special Initiatives 26 th April 2005 Strategy for Industrialization
More informationpresented used in this data must report itself,
Towards a Common Future: Higher Education in the SADC Re egion Regional Country Profiles The country study presented here was prepared as a part of the study The State of Public Science in the SADC Region
More informationRegional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities
DEPARTMENT OF INTELLECTUAL PROPERTY MINISTRY OF COMMERCE Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities Topic 12: Which are Valid Grounds for a Compulsory
More informationQuality assurance in the supply chain for pharmaceuticals from the WHO perspective
1 Quality assurance in the supply chain for pharmaceuticals from the WHO perspective Dr Sabine Kopp Quality Assurance and Safety: Medicines Medicines Policy and Standards World Health Organization Presentation
More informationAndalusian Agency for Health Technology Assessment (AETSA)
Andalusian Agency for Health Technology Assessment (AETSA) Seville, 22 nd of July, 2016 Comments on the concept paper Facilitating the translation of advanced therapies to patients in Europe 1 Introduction
More informationGLOBAL VALUE CHAINS, INDUSTRY 4.0, AND KOREAN INDUSTRIAL TRANSFORMATION
GLOBAL VALUE CHAINS, INDUSTRY 4.0, AND KOREAN INDUSTRIAL TRANSFORMATION September 5, 2017 Professor Gary Gereffi Director Global Value Chains Center Duke University Duke GVC Center research team in collaboration
More informationHigher School of Economics, Vienna
Open innovation and global networks - Symposium on Transatlantic EU-U.S. Cooperation on Innovation and Technology Transfer 22nd of March 2011 - Dr. Dirk Meissner Deputy Head and Research Professor Research
More informationStudy of Comparative Advantages of Chinese and Indian Pharmaceutical Industries under Globalization
MANAGEMENT SCIENCE AND ENGINEERING Vol. 4, No. 4, 2010, pp. 82-86 www.cscanada.org ISSN 1913-0341 [Print] ISSN 1913-035X [Online] www.cscanada.net Study of Comparative Advantages of Chinese and Indian
More informationMedicines Manufacturing in the UK 2017
Medicines Manufacturing in the UK 2017 Moderator: Magda Papadaki, PhD Head of Manufacturing Innovation The Association of the British Pharmaceutical Industry Medicines Manufacturing Industry Partnership
More informationNational Research and Innovation Dialogue Universities South Africa 7 &8 April 2016 Emperors Palace
National Research and Innovation Dialogue Universities South Africa 7 &8 April 2016 Emperors Palace Prof Anastassios Pouris University of Pretoria South Africa International Comparative Study of Funding
More informationResearch Patents in Biotech SMEs
Research Patents in Biotech SMEs Doorways, Obstacles, Fortifications & Bridges Neil Thomas PhD Director of Intellectual Property, Genetrix Group, Madrid, Spain. Agenda 1. Introduction to Genetrix Definition
More informationINVESTOR PRESENTATION!
INVESTOR PRESENTATION ENHANCING HEALTH THROUGH CANNABIS SCIENCE WWW.EMERALDHEALTH.CA TSX.V:EMH TSX.V:EMH Disclaimer THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING
More informationScience, technology and engineering for innovation and capacity-building in education and research UNCTAD Wednesday, 28 November 2007
Science, technology and engineering for innovation and capacity-building in education and research UNCTAD Wednesday, 28 November 2007 I am honored to have this opportunity to present to you the first issues
More informationThe Green Economy: Trade and Sustainable Development Implications. From Rio to Rio:Technology Transfer, Innovation and Intellectual Property
Ad Hoc Expert Meeting on The Green Economy: Trade and Sustainable Development Implications Geneva, Switzerland. 8-10 Nov 2011 From Rio to Rio:Technology Transfer, and Intellectual Property By Mr. Ahmed
More informationGlobalisation increasingly affects how companies in OECD countries
ISBN 978-92-64-04767-9 Open Innovation in Global Networks OECD 2008 Executive Summary Globalisation increasingly affects how companies in OECD countries operate, compete and innovate, both at home and
More informationthe SPD company Dr Clive Simon, Principal, The SPD Company.
the SPD company With decades of local and international experience at the coalface, The SPD Company s specialists have built a solid repertoire of in-depth technical knowledge within the highly-regulated
More informationChanging role of the State in Innovative Activity The Indian Experience. Sunil Mani
Changing role of the State in Innovative Activity The Indian Experience Sunil Mani Outline The two manifestations of state intervention Manifestation 1: State involved directly in the creation of new technologies
More informationThe 21 st APEC Small and Medium Enterprises Ministerial Meeting Joint Ministerial Statement. Nanjing, China September 5, 2014
The 21 st APEC Small and Medium Enterprises Ministerial Meeting Joint Ministerial Statement Nanjing, China September 5, 2014 Innovation and Sustainability Introduction 1. We, the APEC Ministers and their
More informationIn-Country Shared Value Creation The Case of Ghana
In-Country Shared Value Creation The Case of Ghana 6 th Plenary Session, OECD Policy Dialogue on Natural Resource-Based Development Paris, 22 23 June 2016 Isabelle RAMDOO African Minerals Development Centre
More informationThe globalisation of innovation: knowledge creation and why it matters for development
The globalisation of innovation: knowledge creation and why it matters for development Rajneesh Narula Professor of International Business Regulation Innovation and technology innovation: changes in the
More informationZero-Order Review of STI Roadmaps and Strategies
Zero-Order Review of STI Roadmaps and Strategies Nebojsa Deputy Director General International Institute for Applied Systems Analysis Professor Emeritus of Energy Economics Vienna University of Technology
More informationLeader in Pharmaceutical Films
TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Films Your Specialist in Contract Development & Manufacturing WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation
More information13-17 OCTOBER 2008 AU/MIN/ CAMRMRD /4(I) ADDIS ABABA DECLARATION ON DEVELOPMENT AND MANAGEMENT OF AFRICA S MINERAL RESOURCES.
AFRICAN UNION UNION AFRICAINE UNIÃO AFRICANA Addis Ababa, ETHIOPIA P. O. Box 3243 Telephone 517 700 Fax: +251-1-517844 AU CONFERENCE OF MINISTERS RESPONSIBLE 1 ST ORDINARY SESSION 13-17 OCTOBER 2008 AU/MIN/
More informationTRIPS and Access to Medicines. The Story so far
TRIPS and Access to Medicines The Story so far TRIPS and Access to Medicines : A brief history 1981: HIV first clinically observed 1982-83: Named AIDS 1984: Discovery that it is caused by a virus 1986:
More informationA Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei
A Brief Introduction to the Regulatory Environment of Medical Device Supervision CFDA Department of Legal Affairs Liu Pei Development Trend of Medical Device Industry Development Opportunities of Medical
More information(Fig.) JPMA Industry Vision 2025
2. JPMA Industry Vision 2025 Against the background of the changing environment surrounding the pharmaceutical industry and the future predictions *1, we prepared JPMA Industry Vision 2025 Bringing Innovation
More informationTapan Ray Director General Organisation of Pharmaceutical Producers of India ALCAN PACKAGING UNIVERSITY OCT 8, LONAVALA
COMBATING COUNTERFEIT DRUGS WITH PACKAGING TECHNOLOGY Tapan Ray Director General Organisation of Pharmaceutical Producers of India ALCAN PACKAGING UNIVERSITY OCT 8, 2009 -LONAVALA Content Counterfeit Medicines:
More informationAccess to Technology in the Post-2015 Development Agenda. Alessandra Casazza Policy Advisor UNDP Asia-Pacific Regional Center
Access to Technology in the Post-2015 Development Agenda Alessandra Casazza Policy Advisor UNDP Asia-Pacific Regional Center TECHNOLOGY IS ESSENTIAL FOR ACHIEVING SUSTAINABLE DEVELOPMENT MDG 8 ICT & Access
More informationMonitoring R&D resource flows: Global resources and challenges
WHO informal workshop: Wellcome Trust, London 14 February 2013 Monitoring R&D resource flows: Global resources and challenges Stephen Matlin Institute of Global Health Innovation Imperial College, London
More informationHealth & Social Care Industrial Innovation
Health & Social Care Industrial Innovation Mr Andrew Fowlie Scottish Government Health Innovations Team SHINE North Sea Region Program 2014 2020 Scotland s Medical Technologies Landscape Imaging Non Imaging
More informationStarpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
More informationINNOVATION IN DEVELOPING COUNTRIES TO MEET HEALTH NEEDS EXPERIENCES OF BRAZIL, CHINA, INDIA, AND SOUTH AFRICA. An overview report to the
INNOVATION IN DEVELOPING COUNTRIES TO MEET HEALTH NEEDS EXPERIENCES OF BRAZIL, CHINA, INDIA, AND SOUTH AFRICA An overview report to the Commission on Intellectual Property Rights, Innovation and Public
More informationInternational Regulatory Harmonization and Medical Technology Innovation. Some personal thoughts
International Regulatory Harmonization and Medical Technology Innovation Some personal thoughts Tokyo University Tokyo, 13 April 2012 M. Gropp; Medtronic, Inc., Minneapolis, USA 1 Overview Overview of
More informationSTI Roadmaps incorporating SDGs and Implications for Policy and Capacity Building. Klaus Tilmes & Naoto Kanehira World Bank Group November 30, 2017
STI Roadmaps incorporating SDGs and Implications for Policy and Capacity Building Klaus Tilmes & Naoto Kanehira World Bank Group November 30, 2017 0 Outline 1. Reflecting back on the 2017 UN STI Forum
More informationBayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division
Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your
More information- The experience and relevance of EU SMEs support in Asia-
EU-Japan Centre for Industrial Cooperation 日欧産業協力センター EU policy and instruments for innovation and SMEs internationalization - The experience and relevance of EU SMEs support in Asia- Dr. Silviu Jora,
More informationNew Concepts and Trends in International R&D Organisation
New Concepts and Trends in International R&D Organisation (Oliver Gassmann, Maximilian Von Zedtwitz) Prepared by: Irene Goh & Goh Wee Liang Abstract The globalization of markets, the regionalization of
More informationResearch and Innovation Strategy and Action Plan UPDATE Advancing knowledge and transforming lives through education and research
Page 1 of 9 Research and Innovation Strategy and Action Plan 2012 2015 UPDATE Advancing knowledge and transforming lives through education and research Executive Summary As the enterprise university, Plymouth
More informationWHO workshop on IP and Vaccines. Geneva 19 th -20 th April Introduction to the IP issues Christopher Garrison Consultant to WHO
WHO workshop on IP and Vaccines Geneva 19 th -20 th April 2004 Introduction to the IP issues Christopher Garrison Consultant to WHO Vaccine access, R&D and technology transfer issues are intimately linked
More informationTHE SCIENTIFIC AND TECHNOLOGICAL PARK OF SENEGAL
Recteur Abdou Salam Sall, Dakar University, Senegal THE SCIENTIFIC AND TECHNOLOGICAL PARK OF SENEGAL The 21 st century is making ever greater use of knowledge and know-how in every sector of economic and
More informationASIA S GROWTH, PRODUCTION NETWORKS, AND SMES
ASIA S GROWTH, PRODUCTION NETWORKS, AND SMES The escalating Eurozone crisis and signs of spluttering world growth have put Asia and its manufacturing enterprises into the spotlight again. Part of Asia
More informationR&D and innovation activities in companies across Global Value Chains
R&D and innovation activities in companies across Global Value Chains 8th IRIMA workshop Corporate R&D & Innovation Value Chains: Implications for EU territorial policies Brussels, 8 March 2017 Objectives
More informationTRIUMF ACCELERATING CANADIAN BUSINESS THROUGH SCIENCE AND INNOVATION Pre-Budget Consultation
Canada s national laboratory for particle and nuclear physics Laboratoire national canadien pour la recherche en physique nucléaire et en physique des particules TRIUMF ACCELERATING CANADIAN BUSINESS THROUGH
More informationMinistry of. Economic Development
Ministry of Economic Development Ministry of Economic Development Plan of Action Curaçao Innovation Policy Content 1. Basic elements of Innovation Policy 2. Execution of Innovation Policy in 2018 (PoA)
More informationIN-DEPTH ASSESSMENT OF THE SITUATION (CONTRACT NO ENTR/2010/16, LOT 2) Task 6: Research, Development and Innovation in the Footwear Sector
IN-DEPTH ASSESSMENT OF THE SITUATION OF THE EUROPEAN FOOTWEAR SECTOR AND PROSPECTS FOR ITS FUTURE DEVELOPMENT (CONTRACT NO ENTR/2010/16, LOT 2) Task 6: Research, Development and Innovation in the Footwear
More informationCollegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business
More informationFlexibilities in the Patent System
Flexibilities in the Patent System Joseph Straus, Munich WIPO Colloquium on Selected Patents Issues Geneva, February 16, 2007 J. Straus 2007 1 Topics to Consider Facts First Pre-TRIPS-Regime TRIPS & Mandatory
More informationTopic 2: The Critical Role of IP Policies in Modern Economies
Topic 2: The Critical Role of IP Policies in Modern Economies McLean Sibanda Partner: Sibanda & Zantwijk Attorneys, South Africa THE ROLE OF INTELLECTUAL PROPERTY OFFICES (IPOs) IN PROMOTING INNOVATION,
More informationClimate Change Innovation and Technology Framework 2017
Climate Change Innovation and Technology Framework 2017 Advancing Alberta s environmental performance and diversification through investments in innovation and technology Table of Contents 2 Message from
More information